Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors Clinical research trials and UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors. UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors clinical trial. Participants oftentimes recieve the most expert healthcare available for their UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "U" Clinical Trials Conditions > UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors

UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors



UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors

For Condition: unspecified adult solid tumor, protocol specific
Status: Recruiting
Sponsor(s): Norris Cotton Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help cisplatin kill more cancer cells by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining UCN-01 with cisplatin in treating patients who have advanced solid tumors.
Details: OBJECTIVES: - Determine the maximum tolerated dose of cisplatin when administered with UCN-01 in patients with advanced solid tumors. - Determine the toxicity and potential antitumor activity of this regimen in these patients. - Determine the pharmacokinetics of this regimen in these patients. OUTLINE: This is a dose-escalation study of cisplatin. Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of cisplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed every 2-3 months for at least 1 year. PROJECTED ACCRUAL: A total of 9-30 patients will be accrued for this study within 12-18 months.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed advanced or metastatic solid tumor that is not amenable to standard therapy - No brain metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Life expectancy: - More than 3 months Hematopoietic: - WBC at least 4,000/mm^3 - Absolute neutrophil count at least 2,000/mm^3 - Platelet count at least 150,000/mm^3 Hepatic: - Bilirubin normal - SGOT no greater than 2.5 times upper limit of normal Renal: - Creatinine normal - Creatinine clearance at least 60 mL/min Cardiovascular: - No coronary artery disease - No New York Heart Association class III or IV heart disease Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 3 months after study - Must have central indwelling venous catheter - No peripheral neuropathy greater than grade 1 - No prior allergic reaction to diuretics or antiemetics (e.g., 5-HT3 antagonists) to be administered during study - No clinically significant hearing loss - No uncontrolled concurrent illness that would preclude study therapy - No medical, social, or psychological factor that would preclude study therapy PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No more than 2 prior chemotherapy regimens - At least 4 weeks since prior chemotherapy (at least 6 weeks for mitomycin or nitrosoureas) and recovered - Prior cumulative dose of cisplatin no greater than 250 mg/m^2 Endocrine therapy: - Not specified Radiotherapy: - At least 4 weeks since prior radiotherapy and recovered - No prior radiotherapy to the mediastinum - No concurrent radiotherapy Surgery: - Recovered from prior surgery Other: - At least 30 days since prior investigational drugs - No other concurrent investigational drugs - No other concurrent anti-cancer agents
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
RaymondPerez,  Study Chair,  Norris Cotton Cancer Center

Norris Cotton Cancer Center at Dartmouth Medical School *Recruiting*
Lebanon,  New Hampshire,  03756-0002
United States
Recruiting Raymond  Perez 603-650-6633


Additional Information:
Study ID Numbers:  CDR0000068492;  NCI-2331,DMS-9934
Study Start Date: 
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00012194

Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Voriconazole With or Without Interferon gamma in Treating Patients With Aspergillosis or Other Fungal Infections

2. Valeriana Officinalis (Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy

3. Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

4. Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss

5. LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases

Related Studies:

Other unspecified adult solid tumor, protocol specific Clinical Trials
Other New Hampshire Clinical Trials
Other Lebanon Clinical Trials

UCN-01 and Cisplatin in Treating Patients With Advanced Solid Tumors
Modify your Search

  Other unspecified adult solid tumor, protocol specific Clinical Trials
  Other New Hampshire Clinical Trials
  Other Lebanon Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103